Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$29.83 USD

29.83
4,829,456

+0.57 (1.95%)

Updated May 3, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (196 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Seagen's (SGEN) Q1 Earnings and Revenues Miss Expectations

by Zacks Equity Research

Seagen (SGEN) reports worse-than-expected results in the first quarter of 2023, missing both earnings and sales estimates.

Roche (RHHBY) Q1 Revenues Decline on Lower COVID-19 Test Sales

by Zacks Equity Research

Roche's (RHHBY) performance in first-quarter 2023 is pretty ho-hum as COVID-19-test sales continue to decline.

Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs

by Zacks Equity Research

Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading.

AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

AbbVie's (ABBV) Q1 performance will likely reflect declining sales of Humira following the loss of exclusivity. Sales of Rinvoq and Skyrizi are expected to partially offset this fall.

Roche (RHHBY) Polivy Combination for DLBCL Gets Full Approval

by Zacks Equity Research

Roche (RHHBY) gets full approval for Polivy (polatuzumab vedotin-piiq) in combination with Rituxan, cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients who have previously untreated DLBCL.

Biogen (BIIB) to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of multiple sclerosis drugs, while sales of Spinraza are likely to have improved.

Roche (RHHBY) Announces Data on Tecentriq Combo for HCC

by Zacks Equity Research

Roche's (RHHBY) new data from the late-stage IMbrave050 study reveals that the combination of Tecentriq and Avastin reduces the risk of cancer relapsing in people with certain types of adjuvant liver cancer in a phase III study.

Sarepta Down on Reports of FDA Almost Rejecting DMD Gene Therapy

by Zacks Equity Research

Per a Stat News article, the FDA initially considered rejecting Sarepta's (SRPT) regulatory filing seeking FDA's accelerated approval for DMD gene therapy.

Prothena (PRTA) Gains 29% in One Year: Will the Momentum Continue?

by Zacks Equity Research

Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.

Omega Therapeutics, Inc. (OMGA) Surges 19.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Omega Therapeutics, Inc. (OMGA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Pfizer (PFE) Gets FDA Acceptance for Braftovi + Mektovi sNDAs

by Zacks Equity Research

FDA accepts Pfizer's (PFE) sNDAs seeking approval of Braftovi + Mektovi for BRAF V600E-mutant non-small cell lung cancer.

J&J (JNJ) Offers $8.9B Settlement for Talc Cancer Lawsuits

by Zacks Equity Research

To completely resolve its cosmetic talc litigation, J&J (JNJ) offers a settlement amount of $8.9 billion payable over a period of 25 years.

Kodiak Sciences (KOD) Shares are Up 26% in a Week: Here's Why

by Zacks Equity Research

Shares of Kodiak Sciences (KOD) shot up 26% in the last week after the company announced remaining on track with ongoing studies in its fourth-quarter and full-year 2022 earnings report.

The Zacks Analyst Blog Highlights Berkshire Hathaway, Roche Holding, Thermo Fisher Scientific, Mitsubishi UFJ Financial Group and Synopsys

by Zacks Equity Research

Berkshire Hathaway, Roche Holding, Thermo Fisher Scientific, Mitsubishi UFJ Financial Group and Synopsys are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Berkshire Hathaway, Roche & Thermo Fisher Scientific

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Roche Holding AG (RHHBY) and Thermo Fisher Scientific Inc. (TMO).

The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly

by Zacks Equity Research

Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL

by Kinjel Shah

Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951

Roche (RHHBY) & Lilly to Co-Develop Alzheimer's Detection Device

by Zacks Equity Research

Roche (RHHBY) and Lilly announce a collaboration deal to support the development of the former's early diagnosis device for Alzheimer's Disease.

Roche (RHHBY) Polivy Combo Backed by FDA Advisory Committee

by Zacks Equity Research

Roche (RHHBY) gets majority votes from the FDA's Advisory Committee for Polivy combination for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL).

Kinjel Shah headshot

Pharma Stock Roundup: LLY's Alzheimer's Study Setback, FDA Updates for SNY, MRK

by Kinjel Shah

FDA accepts Sanofi's (SNY) Dupixent sBLA. Lilly's (LLY) solanezumab fails to prevent Alzheimer's in a study.

Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study

by Zacks Equity Research

Data from a late-stage study showed that treatment with Eli Lilly's (LLY) solanezumab did not result in the clearance of brain amyloid plaque in people with preclinical Alzheimer's disease.

Exelixis' (EXEL) Cabozantinib Combo Study Fails to Meet Goal

by Zacks Equity Research

Exelixis' (EXEL) combo-drug study for kidney cancer fails to meet the primary endpoint of progression-free survival (PFS).

Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi

by Zacks Equity Research

The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.

RHHBY vs. ABBV: Which Stock Is the Better Value Option?

by Zacks Equity Research

RHHBY vs. ABBV: Which Stock Is the Better Value Option?

Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up

by Zacks Equity Research

Sarepta (SRPT) delivers decent fourth-quarter 2022 results. Management confirms that the FDA does not plan to hold an advisory committee meeting for the DMD gene-therapy filing.